ACTI — Active Biotech AB publ Income Statement
0.000.00%
Last trade - 00:00- SEK113.48m
- SEK48.48m
Annual income statement for Active Biotech AB publ, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 49.8 | 57.9 | 46.5 | 39.8 | 37.6 |
| Operating Profit | -49.8 | -57.9 | -46.5 | -39.8 | -37.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -49.8 | -58.4 | -45.8 | -39.4 | -37.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -49.8 | -58.4 | -45.8 | -39.4 | -37.3 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -49.8 | -58.4 | -45.8 | -39.4 | -37.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -49.8 | -58.4 | -45.8 | -39.4 | -37.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.073 | -0.08 | -0.06 | -0.074 | -0.028 |
| Dividends per Share |